Published in

European Centre for Disease Prevention and Control, Eurosurveillance, 48(27), 2022

DOI: 10.2807/1560-7917.es.2022.27.48.2200894

Links

Tools

Export citation

Search in Google Scholar

Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022

Journal article published in 2022 by Nicole Berens-Riha, Tessa De Block, Johan van Griensven, Jojanneke Rutgers, Johan Michiels, Liesbeth Van Gestel, Matilde Hens, J. Van Griensven, Chris Kenyon, Emmanuel Bottieau, Patrick Soentjens, Isabel Brosius, C. Van Dijck, I. De Baetselier, Kevin K. Ariën and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Vaccination is important in containing the 2022 mpox (formerly monkeypox) epidemic. We describe five Belgian patients with localised severe symptoms of proctitis and penile oedema, occurring between 4 and 35 days after post-exposure preventive vaccination or after one- or two-dose off-label pre-exposure preventive vaccination with MVA-BN vaccine. Genome sequencing did not reveal evidence for immune escape variants. Healthcare workers and those at risk should be aware of possible infections occurring shortly after vaccination and the need for other preventive measures.